Synplogen

News Release

Synplogen Signs Business Alliance Agreement with TAIYO Pharma Tech

KOBE, Japan, November 14, 2023 - Synplogen Co., Ltd. (Head Office: Chuo-ku, Kobe; President and CEO, Representative Director: Kazuhiko Yamamoto; hereinafter referred to as "Synplogen"), a biotech startup spun out of Kobe University, has entered into a business alliance agreement with TAIYO Pharma Tech Co., Ltd. (Head office: Takatsuki, Osaka; President and CEO: Eiji Sato; hereinafter referred to as "TPT"), a wholly owned subsidiary of TAIYO Holdings Co., Ltd., with the aim of development and manufacturing of gene therapy products in Japan.

Synplogen provides design, development, and analysis services ("Gene Therapy Biofoundry™ Services") for high quality, cost-effective gene therapy viral vectors and mRNAs, utilizing its proprietary ultra-long DNA synthesis technology. At its own R&D center in Kobe, Synplogen is able to provide a wide range of services to meet customer needs, from DNA synthesis, plasmid DNA mass preparation, viral vector production, process development, characterization and quality testing, to technology transfer to partner companies' GMP-compliant manufacturing facilities.

The TAIYO Holdings Group is actively developing its business not only in its mainstream electronics business, but also in the medical and pharmaceutical businesses. Since its establishment in April 2019, TPT, which is in charge of contracted pharmaceutical manufacturing business under the group, has been promoting the construction of manufacturing facilities and a manufacturing system for gene therapy products, and in March 2023, a GMP-compliant manufacturing facility for gene therapy products was completed within its Takatsuki factory.

With the signing of the business alliance agreement, the two companies have agreed to develop a culture and purification process for gene therapy products and to establish an operational system for their mutual use. Taking advantage of the close proximity of Kobe and Takatsuki, Osaka, the two companies will establish a system that enables the prompt transfer of gene therapy products, designed and developed through Synplogen's Gene Therapy Biofoundry™ Services, to TPT’s GMP manufacturing facility (Figure 1).

Synplogen will contribute to the commercialization of innovative gene therapy products by establishing an integrated value chain in Japan (in the Kobe/Osaka area) that can flexibly handle the design, development, and GMP manufacturing of gene therapy products such as AAV vectors, even for small-lot, multi-product manufacturing.

(Figure 1) Value chain for gene therapy products development



About Synplogen Co., Ltd.

Synplogen Co., Ltd. is a synthetic biology startup company founded in 2017 and originated from Kobe University. Utilizing its proprietary DNA synthesis technologies, "OGAB™ method" and "Combi-OGAB™ method", the company is capable of synthesizing ultra-long and complex DNA and constructing DNA libraries with various combinations. We also provide one-stop solution services from design, development, analysis to technology transfer of high-quality, cost-effective viral vectors for gene therapy at our R&D Center in Kobe, as a biofoundry specializing in gene therapy.

Head Office:	CLIK4F, 6-3-7 Minatojima-Minamimachi Chuo-ku, Kobe Japan
Established:	February 2017
Representative:	Kazuhiko Yamamoto, President and CEO, Representative Director
Capital:	JPY 3,247.28 million (including capital reserve)
Business:	Custom DNA synthesis and Gene Therapy Biofoundry™ services
URL:	https://www.synplogen.com/en/

About TAIYO Pharma Tech Co., Ltd.

Head Office:	4-38 Aketa-cho, Takatsuki Osaka Japan
Established:	April 2019
Representative:	Eiji Sato, President and CEO
Capital:	JPY 300 million
Business:	Contracted Manufacturing Organization
URL:	https://www.taiyo-pt.co.jp/en/

Contact:
Synplogen Co., Ltd.
Email: info@synplogen.com